Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AbbVie
Biotech
AbbVie's $9B schizophrenia prospect flunks phase 2 trials
The candidate at the center of AbbVie’s $8.7 billion Cerevel acquisition has failed a pair of phase 2 trials, delivering a boost to rival BMS.
Nick Paul Taylor
Nov 11, 2024 10:06am
AbbVie pays $65M for options on EvolveImmune's T-cell engagers
Oct 31, 2024 10:00am
AbbVie inks $1.4B Aliada buyout to land ex-J&J Alzheimer's drug
Oct 28, 2024 10:00am
AbbVie makes Richter richer, paying $25M to form discovery pact
Oct 25, 2024 7:55am
AbbVie Parkinson's drug from $8.7B Cerevel buyout scores
Sep 26, 2024 10:45am
AbbVie sues BeiGene over blood cancer drug trade secrets
Sep 11, 2024 10:17am
